File Download
 
Links for fulltext
(May Require Subscription)
 
Supplementary

Conference Paper: Impact of antiviral therapy on the survival outcome of patients after major hepatectomy for hepatitis B-related hepatocellular carcinoma
  • Basic View
  • Metadata View
  • XML View
TitleImpact of antiviral therapy on the survival outcome of patients after major hepatectomy for hepatitis B-related hepatocellular carcinoma
 
AuthorsChan, ACY
Chok, K
Yuen, WK
Poon, R
Lo, CM
Fan, ST
 
KeywordsMedical sciences
Endocrinology
 
Issue Date2011
 
PublisherSpringer New York LLC. The Journal's web site is located at http://www.springer.com/west/home/medicine?SGWID=4-10054-70-173733513-0
 
CitationThe 21st Conferece of the Asian Pacific Association for the Study of the Liver (APASL 2011), Bangkok, Thailand, 17-20 February 2011. In Hepatology International, 2011, v. 5 n. 1, p. 419-420, abstract no. PP29-05 [How to Cite?]
DOI: http://dx.doi.org/10.1007/s12072-010-9241-z
 
AbstractBACKGROUND: Although the therapeutic benefit of anti-viral treatment in the management of chronic hepatitis B infection (HBV) is well established, it remains uncertain if commencement of anti-viral therapy after hepatectomy in anti-viral naïve patients with hepatocellular carcinoma (HCC) would improve their survival outcome. METHODS: From September 2003 to December 2007, 42 patients (i.e. treatment group) were given Lamivudine (n = 39) or Entecavir(n = 4) after hepatectomy for HBV-related HCC. All these patients were anti-viral naïve before hepatectomy. Their preoperative data, tumor characteristics and survival outcome were compared with 94 patients without any antiviral treatment after hepatectomy (i.e. control group). RESULTS: The median age for treatment and control group were 57 and 55 years old respectively (P = 0.77). Patient demographics, preoperative liver function, tumor characteristics, liver function at the time of tumor recurrence were comparable between the two groups. Both disease-free and overall survival rates were significantly improved in the treatment group. The 1-, 3-, and 5-year overall survival rate in the treatment group was 88.1, 79.1, and 71.2% respectively, and in the control group was 76.5, 47.5, and 43.5% respectively (P = 0.005). The 1-, 3- and 5-year disease-free survival rate in the treatment group was 66.5, 51.4, and 51.4% respectively, and in the control group was 48.9, 33.8, and 33.8% respectively (P = 0.05). Subgroup analysis stratified against tumour stage and portal vein status showed that post-hepatectomy antiviral treatment confers a significant survival benefit in AJCC stage I/II tumours or HCCs without portal vein invasion. CONCLUSION: Anti-viral naïve HBV carriers could still benefit from the therapeutic effect of anti-viral treatment after curative treatment for hepatocellular carcinoma.
 
DescriptionOral Presentations
 
ISSN1936-0533
2013 Impact Factor: 2.468
 
DOIhttp://dx.doi.org/10.1007/s12072-010-9241-z
 
ISI Accession Number IDWOS:000300105300001
 
DC FieldValue
dc.contributor.authorChan, ACY
 
dc.contributor.authorChok, K
 
dc.contributor.authorYuen, WK
 
dc.contributor.authorPoon, R
 
dc.contributor.authorLo, CM
 
dc.contributor.authorFan, ST
 
dc.date.accessioned2011-07-27T02:02:44Z
 
dc.date.available2011-07-27T02:02:44Z
 
dc.date.issued2011
 
dc.description.abstractBACKGROUND: Although the therapeutic benefit of anti-viral treatment in the management of chronic hepatitis B infection (HBV) is well established, it remains uncertain if commencement of anti-viral therapy after hepatectomy in anti-viral naïve patients with hepatocellular carcinoma (HCC) would improve their survival outcome. METHODS: From September 2003 to December 2007, 42 patients (i.e. treatment group) were given Lamivudine (n = 39) or Entecavir(n = 4) after hepatectomy for HBV-related HCC. All these patients were anti-viral naïve before hepatectomy. Their preoperative data, tumor characteristics and survival outcome were compared with 94 patients without any antiviral treatment after hepatectomy (i.e. control group). RESULTS: The median age for treatment and control group were 57 and 55 years old respectively (P = 0.77). Patient demographics, preoperative liver function, tumor characteristics, liver function at the time of tumor recurrence were comparable between the two groups. Both disease-free and overall survival rates were significantly improved in the treatment group. The 1-, 3-, and 5-year overall survival rate in the treatment group was 88.1, 79.1, and 71.2% respectively, and in the control group was 76.5, 47.5, and 43.5% respectively (P = 0.005). The 1-, 3- and 5-year disease-free survival rate in the treatment group was 66.5, 51.4, and 51.4% respectively, and in the control group was 48.9, 33.8, and 33.8% respectively (P = 0.05). Subgroup analysis stratified against tumour stage and portal vein status showed that post-hepatectomy antiviral treatment confers a significant survival benefit in AJCC stage I/II tumours or HCCs without portal vein invasion. CONCLUSION: Anti-viral naïve HBV carriers could still benefit from the therapeutic effect of anti-viral treatment after curative treatment for hepatocellular carcinoma.
 
dc.descriptionOral Presentations
 
dc.description.otherThe 21st Conferece of the Asian Pacific Association for the Study of the Liver (APASL 2011), Bangkok, Thailand, 17-20 February 2011. In Hepatology International, 2011, v. 5 n. 1, p. 419-420, abstract no. PP29-05
 
dc.identifier.citationThe 21st Conferece of the Asian Pacific Association for the Study of the Liver (APASL 2011), Bangkok, Thailand, 17-20 February 2011. In Hepatology International, 2011, v. 5 n. 1, p. 419-420, abstract no. PP29-05 [How to Cite?]
DOI: http://dx.doi.org/10.1007/s12072-010-9241-z
 
dc.identifier.doihttp://dx.doi.org/10.1007/s12072-010-9241-z
 
dc.identifier.epage420
 
dc.identifier.hkuros188334
 
dc.identifier.isiWOS:000300105300001
 
dc.identifier.issn1936-0533
2013 Impact Factor: 2.468
 
dc.identifier.issue1
 
dc.identifier.openurl
 
dc.identifier.spage419
 
dc.identifier.urihttp://hdl.handle.net/10722/136094
 
dc.identifier.volume5
 
dc.languageeng
 
dc.publisherSpringer New York LLC. The Journal's web site is located at http://www.springer.com/west/home/medicine?SGWID=4-10054-70-173733513-0
 
dc.relation.ispartofHepatology International
 
dc.rightsThe original publication is available at www.springerlink.com
 
dc.subjectMedical sciences
 
dc.subjectEndocrinology
 
dc.titleImpact of antiviral therapy on the survival outcome of patients after major hepatectomy for hepatitis B-related hepatocellular carcinoma
 
dc.typeConference_Paper
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Chan, ACY</contributor.author>
<contributor.author>Chok, K</contributor.author>
<contributor.author>Yuen, WK</contributor.author>
<contributor.author>Poon, R</contributor.author>
<contributor.author>Lo, CM</contributor.author>
<contributor.author>Fan, ST</contributor.author>
<date.accessioned>2011-07-27T02:02:44Z</date.accessioned>
<date.available>2011-07-27T02:02:44Z</date.available>
<date.issued>2011</date.issued>
<identifier.citation>The 21st Conferece of the Asian Pacific Association for the Study of the Liver (APASL 2011), Bangkok, Thailand, 17-20 February 2011. In Hepatology International, 2011, v. 5 n. 1, p. 419-420, abstract no. PP29-05</identifier.citation>
<identifier.issn>1936-0533</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/136094</identifier.uri>
<description>Oral Presentations</description>
<description.abstract>BACKGROUND: Although the therapeutic benefit of anti-viral treatment in the management of chronic hepatitis B infection (HBV) is well established, it remains uncertain if commencement of anti-viral therapy after hepatectomy in anti-viral na&#239;ve patients with hepatocellular carcinoma (HCC) would improve their survival outcome. METHODS: From September 2003 to December 2007, 42 patients (i.e. treatment group) were given Lamivudine (n = 39) or Entecavir(n = 4) after hepatectomy for HBV-related HCC. All these patients were anti-viral na&#239;ve before hepatectomy. Their preoperative data, tumor characteristics and survival outcome were compared with 94 patients without any antiviral treatment after hepatectomy (i.e. control group). RESULTS: The median age for treatment and control group were 57 and 55 years old respectively (P = 0.77). Patient demographics, preoperative liver function, tumor characteristics, liver function at the time of tumor recurrence were comparable between the two groups. Both disease-free and overall survival rates were significantly improved in the treatment group. The 1-, 3-, and 5-year overall survival rate in the treatment group was 88.1, 79.1, and 71.2% respectively, and in the control group was 76.5, 47.5, and 43.5% respectively (P = 0.005). The 1-, 3- and 5-year disease-free survival rate in the treatment group was 66.5, 51.4, and 51.4% respectively, and in the control group was 48.9, 33.8, and 33.8% respectively (P = 0.05). Subgroup analysis stratified against tumour stage and portal vein status showed that post-hepatectomy antiviral treatment confers a significant survival benefit in AJCC stage I/II tumours or HCCs without portal vein invasion. CONCLUSION: Anti-viral na&#239;ve HBV carriers could still benefit from the therapeutic effect of anti-viral treatment after curative treatment for hepatocellular carcinoma.</description.abstract>
<language>eng</language>
<publisher>Springer New York LLC. The Journal&apos;s web site is located at http://www.springer.com/west/home/medicine?SGWID=4-10054-70-173733513-0</publisher>
<relation.ispartof>Hepatology International</relation.ispartof>
<rights>The original publication is available at www.springerlink.com</rights>
<subject>Medical sciences</subject>
<subject>Endocrinology</subject>
<title>Impact of antiviral therapy on the survival outcome of patients after major hepatectomy for hepatitis B-related hepatocellular carcinoma</title>
<type>Conference_Paper</type>
<identifier.openurl>http://library.hku.hk:4550/resserv?sid=HKU:IR&amp;issn=1936-0533&amp;volume=5&amp;issue=1&amp;spage=419&amp;epage=420, abstract no. PP29&amp;date=2011&amp;atitle=Impact+of+antiviral+therapy+on+the+survival+outcome+of+patients+after+major+hepatectomy+for+hepatitis+B-related+hepatocellular+carcinoma</identifier.openurl>
<identifier.doi>10.1007/s12072-010-9241-z</identifier.doi>
<identifier.hkuros>188334</identifier.hkuros>
<identifier.volume>5</identifier.volume>
<identifier.issue>1</identifier.issue>
<identifier.spage>419</identifier.spage>
<identifier.epage>420</identifier.epage>
<identifier.isi>WOS:000300105300001</identifier.isi>
<description.other>The 21st Conferece of the Asian Pacific Association for the Study of the Liver (APASL 2011), Bangkok, Thailand, 17-20 February 2011. In Hepatology International, 2011, v. 5 n. 1, p. 419-420, abstract no. PP29-05</description.other>
</item>